BRPI1015019A2 - controle de glicosilação de proteína e composições e métodos relacionada a ele. - Google Patents

controle de glicosilação de proteína e composições e métodos relacionada a ele.

Info

Publication number
BRPI1015019A2
BRPI1015019A2 BRPI1015019A BRPI1015019A BRPI1015019A2 BR PI1015019 A2 BRPI1015019 A2 BR PI1015019A2 BR PI1015019 A BRPI1015019 A BR PI1015019A BR PI1015019 A BRPI1015019 A BR PI1015019A BR PI1015019 A2 BRPI1015019 A2 BR PI1015019A2
Authority
BR
Brazil
Prior art keywords
protein
methods
related compositions
glycosylation control
glycosylation
Prior art date
Application number
BRPI1015019A
Other languages
English (en)
Inventor
Lee Ruble Derrick
Gene Combs Rodney
Roe Susanna
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI1015019A2 publication Critical patent/BRPI1015019A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1015019A 2009-04-20 2010-04-15 controle de glicosilação de proteína e composições e métodos relacionada a ele. BRPI1015019A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17089709P 2009-04-20 2009-04-20
PCT/IB2010/051650 WO2010122460A1 (en) 2009-04-20 2010-04-15 Control of protein glycosylation and compositions and methods relating thereto

Publications (1)

Publication Number Publication Date
BRPI1015019A2 true BRPI1015019A2 (pt) 2018-02-14

Family

ID=42536300

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015019A BRPI1015019A2 (pt) 2009-04-20 2010-04-15 controle de glicosilação de proteína e composições e métodos relacionada a ele.

Country Status (12)

Country Link
US (2) US9034341B2 (pt)
EP (1) EP2421892A1 (pt)
JP (1) JP2010246541A (pt)
KR (1) KR20110139292A (pt)
CN (1) CN102803292A (pt)
AU (1) AU2010240569A1 (pt)
BR (1) BRPI1015019A2 (pt)
CA (1) CA2757079C (pt)
IL (1) IL215480A0 (pt)
MX (1) MX2011010989A (pt)
RU (1) RU2011142230A (pt)
WO (1) WO2010122460A1 (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
KR101793195B1 (ko) 2009-03-27 2017-11-02 아카데미아 시니카 바이러스에 대한 면역을 위한 방법 및 조성물
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
EP2678030A4 (en) * 2011-02-25 2015-02-18 Merck Sharp & Dohme PREPARATION OF N- AND O-SIALYLATED TNFRII-FC FUSION PROTEINS IN YEAST
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
CA2929937C (en) * 2012-09-11 2020-01-07 The Regents Of The University Of California Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
TWI793159B (zh) * 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015080973A1 (en) * 2013-11-26 2015-06-04 Baylor College Of Medicine A novel sars immunogenic composition
ES2749862T3 (es) 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
CN106170554B (zh) * 2014-01-29 2021-08-17 美国安进公司 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化
JP6814634B2 (ja) * 2014-02-05 2021-01-20 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. リボ毒性の一時的な減少に基づき、細胞毒性組換えポリペプチドをスクリーニングし、選択し、同定する方法
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
KR102496206B1 (ko) 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
KR102007930B1 (ko) * 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
WO2016126950A1 (en) 2015-02-05 2016-08-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7122974B2 (ja) 2016-05-11 2022-08-22 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 変異免疫グロブリン結合ポリペプチド
EP3455241B1 (en) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Method of cleaning and/or sanitizing a separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
CN106309458A (zh) * 2016-07-28 2017-01-11 中南大学湘雅医院 2‑脱氧‑d‑葡萄糖及其在药学上可接受的盐在制备治疗银屑病药物方面的应用
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN106399286B (zh) * 2016-10-18 2019-12-24 江南大学 一种促进毕赤酵母产碱性果胶酶的方法
MX2019006656A (es) 2016-12-07 2019-09-09 Molecular Templates Inc Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
EP3418298A1 (en) * 2017-06-23 2018-12-26 Universität Heidelberg Rage proteins for the treatment of fibrosis and dna damage mediated diseases
KR20190065234A (ko) * 2017-11-30 2019-06-11 그리폴스 다이어그노스틱 솔루션즈 인크. 면역 관문 억제제인 pd-1 및 pd-l1에 대한 항체 치료를 모니터링하기 위한 면역분석 및 조작된 단백질
JP7267284B2 (ja) * 2017-12-20 2023-05-01 アレス トレーディング ソシエテ アノニム ポリエーテルイオノフォアを使用するタンパク質マンノシル化プロファイルの調節方法
CN108179149B (zh) * 2018-01-03 2021-03-23 青岛瑞斯凯尔生物科技有限公司 S100b突变体及其应用
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
CN110749736A (zh) * 2018-07-24 2020-02-04 中国科学院大连化学物理研究所 一种基于化学反应简化的O-GalNAc糖基化肽段鉴定方法
CA3107038A1 (en) * 2018-08-10 2020-02-13 Genentech, Inc. Cell culture strategies for modulating protein glycosylation
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
CN109726510B (zh) * 2019-01-23 2022-12-23 山东大学 一种蛋白质糖化位点鉴定方法
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
AR125255A1 (es) * 2021-04-02 2023-06-28 Regeneron Pharma Métodos de predicción y modulación de la glicación de una proteína
CN113674367B (zh) * 2021-08-20 2024-03-26 上海宝藤生物医药科技股份有限公司 一种电泳后脂蛋白胆固醇试剂扫描图的预处理方法
CN116124914B (zh) * 2022-11-07 2025-10-17 盛禾(中国)生物制药有限公司 一种异源二聚体蛋白纯度的检测方法
WO2026015533A1 (en) * 2024-07-09 2026-01-15 Alexion Pharmaceuticals, Inc. Methods of manufacturing recombinant alkaline phosphatases

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
NO315930B1 (no) 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
EP0808163B1 (en) 1995-01-18 2003-07-23 Alteon, Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
WO1996031537A1 (en) 1995-04-05 1996-10-10 The Picower Institute For Medical Research Agents for binding to advanced glycosylation endproducts, and methods of their use
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US7081241B1 (en) 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
EP1007048A4 (en) 1997-03-11 2004-09-22 Gen Hospital Corp IDENTIFICATION OF MEANS FOR TREATING ALZHEIMERISCHEN DISEASE
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
WO2000018970A1 (fr) 1998-09-29 2000-04-06 Asahi Kasei Kabushiki Kaisha Procede de commande de liberation de granules
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
AU765719B2 (en) 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6787566B2 (en) 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6605642B2 (en) 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
JP2003507013A (ja) 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのRAGEへの結合を阻害する方法及びその結果
EP1219639A4 (en) 1999-09-08 2009-03-25 Toray Industries CIPO - Patent
US20050170382A1 (en) 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
IL143936A0 (en) 1999-10-21 2002-04-21 Univ Case Western Reserve Gene expression profiling of inflammatory bowel disease
CA2382165A1 (en) 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins
JP3920641B2 (ja) 2000-04-14 2007-05-30 ナイアダイン コーポレーション タンパク質−後期糖化反応生成物(タンパク質−age)形成の調節因子を同定する方法
US20010041349A1 (en) 2000-04-17 2001-11-15 Andrew Patron Protein expression system arrays and use in biological screening
AU2001259710A1 (en) 2000-05-09 2001-11-20 Genetics Institute, Llc Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6563015B1 (en) 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
WO2002029091A2 (en) 2000-10-02 2002-04-11 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
AU2002213192A1 (en) 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US20050244849A1 (en) 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
PL366250A1 (en) 2000-12-29 2005-01-24 Reddy Us Therapeutics, Inc. Detection of compounds that modulate inflammatory responses
US6946277B2 (en) 2001-01-31 2005-09-20 Council Of Scientific And Industrial Research Method for enhancing cellobiase activity of termitomyces clypeatus using a glycosylation inhibitor
PL362324A1 (en) 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
DE10109466B4 (de) 2001-02-28 2008-01-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Mittel zur Modifikation humaner Angiogenese
JP3837494B2 (ja) 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型rageタンパク質
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
MXPA05001758A (es) 2002-08-16 2005-08-19 Wyeth Corp Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage).
CN102268094A (zh) * 2002-08-30 2011-12-07 比奥雷克西斯药物公司 被修饰的转铁蛋白抗体的融合蛋白
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
JP2006525784A (ja) 2002-12-13 2006-11-16 リセンチア エルテーデー 膜貫通型タンパク質amigoおよびその用途
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8067371B2 (en) 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
CN1805743A (zh) 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
WO2005021710A2 (en) 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
CN1874782A (zh) 2003-09-05 2006-12-06 纽约市哥伦比亚大学信托人 治疗肾小球损伤的rage-相关方法与组合物
WO2005042032A1 (en) 2003-10-31 2005-05-12 The Trustees Of Columbia University In The City Of New York Methods for treating multiple sclerosis
US8003613B2 (en) 2003-11-17 2011-08-23 University Of Florida Research Foundation, Inc. Methods and compositions for inducing apoptosis
WO2005051995A2 (en) 2003-11-19 2005-06-09 Curagen Corporation Novel advanced glycosylation end product-specific receptor-like protein and nucleic acids encoding same
GB0330079D0 (en) 2003-12-20 2004-02-04 Bioinvent Int Ab Vaccine
CN100342017C (zh) 2004-05-10 2007-10-10 中国医学科学院肿瘤医院肿瘤研究所 基因重组趋化抗原疫苗
PT1768677E (pt) 2004-07-02 2008-10-06 Creabilis Therapeutics Spa Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1
WO2006012373A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
WO2006012415A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
ES2473587T3 (es) 2004-08-03 2014-07-07 Transtech Pharma, Inc. Proteínas de fusión de RAGE y métodos de uso
EP1776459A1 (en) 2004-08-03 2007-04-25 Transtech Pharma, Inc. Rage fusion proteins and methods of use
EP1799700A4 (en) 2004-09-27 2009-02-11 Centocor Inc SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES
US20070087406A1 (en) 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US20080207499A1 (en) 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
EP1954815B1 (en) * 2005-11-15 2015-02-25 GlycoFi, Inc. Production of glycoproteins with reduced o-glycosylation
US20080311122A1 (en) * 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
WO2007094926A2 (en) 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
MX2008011933A (es) * 2006-03-21 2008-12-18 Wyeth Corp Metodos y composiciones para antagonismo de rage.
EA017291B1 (ru) 2006-05-05 2012-11-30 Транстек Фарма, Инк. Белки слияния на основе rage, их композиции и способы их применения
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
US8376978B2 (en) 2007-02-09 2013-02-19 Baxter International Inc. Optical access disconnection systems and methods
WO2008100470A2 (en) 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
UY30994A1 (es) * 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
US8398977B2 (en) 2007-06-14 2013-03-19 Galactica Pharmaceuticals, Inc. Rage fusion proteins
FR2917883B1 (fr) 2007-06-20 2009-11-27 Jean-Francois Ribatto Systeme pour rendre autonome une machine automatique electronique a peage de lecture d'enregistrements sonores et/ou audio-visuels.

Also Published As

Publication number Publication date
MX2011010989A (es) 2012-02-28
EP2421892A1 (en) 2012-02-29
WO2010122460A1 (en) 2010-10-28
US20120039908A1 (en) 2012-02-16
CA2757079C (en) 2015-05-19
JP2010246541A (ja) 2010-11-04
KR20110139292A (ko) 2011-12-28
RU2011142230A (ru) 2013-05-27
CA2757079A1 (en) 2010-10-28
US9034341B2 (en) 2015-05-19
US20150210749A1 (en) 2015-07-30
AU2010240569A1 (en) 2011-10-20
IL215480A0 (en) 2011-12-29
CN102803292A (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
IL215480A0 (en) Control of protein glycosylation and compositions and methods relating thereto
BRPI1010307A2 (pt) composições e métodos relacionados à variantes de proteína a (spa).
BR112012004402A2 (pt) glicosilação de proteína
PT2406399T (pt) Proteínas mirac
EP2418166A4 (en) ELEVATOR SPEED LIMITER
BRPI0910269A2 (pt) métodos e composições para controle de pestes
BRPI0908728A2 (pt) Material de controle de retorno
BRPI0924162A2 (pt) válvula de controle, e, conjunto de guarnição de válvula
SI2126093T1 (sl) Izboljšanje priprave proteinov
EP2436067A4 (en) AQUEOUS COMPOSITION OF VINYLIDENE POLYFLUORIDE
BRPI0914246A2 (pt) controle de panoramização e ampliação
UA21650S (uk) Пульт дистанційного керування
DK2422086T3 (da) Afdækning til en arkitektonisk åbning
HRP20170138T1 (hr) Ponovno dobivanje proteina
DOP2011000347A (es) Proteina de enlace de il-13
DK2216492T3 (da) Overdækning til en arkitekonisk åbning
BRPI0812776A2 (pt) Controle de ectoparasitas
BR112012000281A2 (pt) proteína quimérica.
BRPI1011740A2 (pt) vidro de controle solar e vidro duplo de controle solar.
BR112012004392A2 (pt) válvula de controle.
EP2094148A4 (en) METHOD OF CONTROLLING DISHWASHER
BRPI1008491A2 (pt) Composição de controle de peste
BRPI1014363A2 (pt) braçadeiras para controle de insetos
BR112012006472A2 (pt) metodo e meiso para um controle arremessavel de jogo
BR112012004446A2 (pt) "válvula de controle"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]